Zenith Thoraco+ Endovascular System (Thoraco+) has received Breakthrough Device Designation from the US Food and Drug Administration (FDA). This designation is granted to devices that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.
While the product is not commercially available yet, the benefits of the designation include priority review and interactive and timely communication with the FDA during the clinical trial and pre-market review phases in order to help get lifesaving devices to patients more quickly.
The Thoraco+ is the second product from Cook Medical to receive a Breakthrough Device Designation in 2022.
“We are excited to receive an FDA Breakthrough Device Designation for the Thoaraco+. This will be a great addition to our portfolio of aortic products so we can offer treatments to a wider variety of patients,” said Mark Breedlove, senior vice president of Cook Medical’s Vascular division.
The Thoraco+ is built on the strength of the proven Zenith platform and represents a next-generation endovascular graft for the treatment of thoracoabdominal aortic aneurysms. The system is indicated for the endovascular treatment of patients with thoracoabdominal aortic aneurysms (Crawford classification I-IV).
The Thoraco+ is an off-the-shelf device incorporating four side branches for the celiac artery, superior mesenteric artery, left renal artery, and right renal artery. To accommodate varied patient anatomy, the Thoraco+ will be available in a range of diameters and lengths.
To learn more about the Breakthrough Device Designation program, visit the FDA’s website. To learn more about Cook Medical’s aortic intervention products, visit our website.